Bio-Techne Corporation’s Advanced Cell Diagnostics (ACD) has reached a significant milestone by surpassing 10,000 peer-reviewed publications that reference the use and application of RNAscope™ ISH technology. The majority of these publications were released in the past three years, as ACD’s leadership in spatial biology applications has become solidified due to increasing global customer awareness and expanded market adoption.
As a pioneer in spatial biology, Bio-Techne offers a wide range of over 50,000 unique RNAscope™ ISH probes spanning across over 400 species. These probes allow biopharma and academic customers to make groundbreaking biologic discoveries, accelerate the development of next-generation therapeutics, and deliver life-changing diagnostics. With single-molecule sensitivity and unrivaled specificity at subcellular resolution, RNAscope™ is the most referenced spatial biology technology in the industry for RNA biomarkers.
The portfolio of 10,000 scientific publications includes applications in cancer, neuroscience, immunology, infectious disease, cell and gene therapy, and regenerative medicine. Bio-Techne’s Diagnostics & Genomics Segment President Matt McManus expressed his excitement about reaching this milestone: “We are thrilled to celebrate the achievement of over 10,000 publications referencing RNAscope™ ISH technology. We are honored by the trust the scientific community has placed in RNAscope™ to uncover new spatial insights and enable significant breakthroughs across a wide range of diseases.”
